| 1 | A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. (Likar Y, Zurita J, Dobrenkov K, Shenker L, Cai S, Neschadim A, Medin JA, Sadelain M, Hricak H, Ponomarev V) J Nucl Med 2010 Sep;51(9):1395-403 51 Citations |
| 1 | Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. (Neschadim A, Wang JC, Sato T, Fowler DH, Lavie A, Medin JA) Mol Ther 2012 May;20(5):1002-13 18 Citations |
| 1 | Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. (Neschadim A, Wang JC, Lavie A, Medin JA) Cancer Gene Ther 2012 May;19(5):320-7 20 Citations |
| 1 | Potent methyl oxidation of 5-methyl-2'-deoxycytidine by halogenated quinoid carcinogens and hydrogen peroxide via a metal-independent mechanism. (Shao J, Huang CH, Kalyanaraman B, Zhu BZ) Free Radic Biol Med 2013 Jul;60:177-82 41 Citations |
| 1 | Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis. (Shire A, Lomberk G, Lai JP, Zou H, Tsuchiya N, Aderca I, Moser CD, Gulaid KH, Oseini A, Hu C, Warsame O, Jenkins RB, Roberts LR) Med Epigenet 2015;3(1):1-18 |
| 1 | Engineered Thymidine-Active Deoxycytidine Kinase for Bystander Killing of Malignant Cells. (Neschadim A, Medin JA) Methods Mol Biol 2019;1895:149-163 |
© 2023 Clinical & Translational Science Institute